• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[히트뉴스] “큐로셀, 국산 첫 CAR-T 신약 허가 정조준… 연내 상장 목표”

2023/07/17

“큐로셀, 국산 첫 CAR-T 신약 허가 정조준… 연내 상장 목표” < 피플 < 기사본문 – 히트뉴스 (hitnews.co.kr)

히트뉴스 남대열 기자

Prev큐로셀, 국제림프종학회에서 차세대 CD19 CAR-T 치료제 임상2상 중간결과 공개
Next큐로셀, 성인 급성림프구성백혈병 CAR-T 치료제 임상시험 첫 환자 투여완료
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.